We hypothesized that the patients in the GATA3+ group were more susceptible to severe complications (such as severe B symptoms, HLH, etc.)when initiating a treatment regimen, leading to morbidity and mortality prior to the effects of chemotherapy. Here, GATA3 is linked to hemophagocytic syndrome.